Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.

Molecular cancer therapeutics - 1 Mar 2008

Kim Hwang-Phill, Han Sae-Won, Kim Sung-Hak, Im Seock-Ah, Oh Do-Youn, Bang Yung-Jue, Kim Tae-You

Abstract excerpt

Although non-small cell lung cancer (NSCLC) cells with somatic mutations in their epidermal growth factor receptors (EGFR) initially show a dramatic response to tyrosine kinase inhibitor (TKI), these cells eventually develop resistance to TKI. This resistance may be caused by a secondary T790M mu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Cetuximab
Share to Chlorocebus aethiops

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dimerization

Share to Gefitinib

Share to Genes, erbB-2

Share to Lapatinib

Share to Quinazolines

Source

Identifiers

PMID: 18347147
DOI: 10.1158/1535-7163.MCT-07-2068

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18347147-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.PMID 18347147Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation.Semantic proximity Read ↗

A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.Semantic proximity Read ↗

A phase 1 study of cetuximab and lapatinib in patients with advanced solid tumor malignancies.Semantic proximity Read ↗

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.Semantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Synergistic cytotoxicity of afatinib and cetuximab against EGFR T790M involves Rab11-dependent EGFR recycling.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.Semantic proximity Read ↗

Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.Semantic proximity Read ↗

Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.Semantic proximity Read ↗

Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.